MIL62 Plus Lenalidomide for Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (FL and MZL)
Condition: Follicular Lymphoma and Marginal Zone Lymphoma Interventions: Drug: Recombinant Humanized Monoclonal Antibody MIL62 Injection; Drug: Lenalidomide Sponsor: Beijing Mabworks Biotech Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials